Saad Usmani, MD, Chief, Plasma Cell Disorders Program, Hematologic Malignancies, Levine Cancer Institute/Atrium Health, UNC Chapel Hill School of Medicine, compares intravenous daratumumab versus subcutaneous daratumumab.
IV Daratumumab versus Subcutaneous Daratumumab
